Research Article
Adult-onset Still's Disease in a Health Center: A Report of 10 Cases
Jean Noel Diokel Ndour*
,
Bachir Mansour Diallo,
Fulgence Faye,
Aicha Kaneye,
Melissa Derneville,
Eunice Thiendrbéogo,
Amy Dioum,
Atoumane Faye,
Adama Berthé,
Papa Souleymane Touré,
Madoky Magatte Diop,
Mamadou Mourtalla Ka
Issue:
Volume 12, Issue 6, December 2024
Pages:
104-109
Received:
20 September 2024
Accepted:
11 October 2024
Published:
13 November 2024
Abstract: Introduction: Adult-onset Still's disease is a rare systemic inflammatory disease in Africa. Observations have been published in Senegal. Materials and Methods: We conducted a retrospective descriptive study to establish the epidemiological profile of patients presenting with adult-onset Still's disease (AOSD) in a health center. The patients included met the diagnostic criteria of Fautrel and/or Yamaguchi. Results: During our study (2020-2024), we included 10 patients with a hospital incidence of 2 patients per year. The average age of the patients was 29.5 years ±11.9, ranging from 15 to 49 years. Females predominated with a sex ratio of 0.67. Clinical manifestations were polymorphic, dominated by fever (100%), inflammatory polyarthralgia (60%), tachycardia (80%), physical asthenia (70%), altered general condition (50%), and erythema (30%). The biological inflammatory syndrome was found in all patients. The glycosylated fraction of ferritin was depleted in all patients. We noted a good outcome after treatment with prednisone 1 mg/kg/day in all patients, methotrexate in six patients, and hydroxychloroquine in one patient. Conclusion: Adult-onset Still's disease is a rare condition, unknown to most practitioners. Its prognosis is severe, especially with visceral involvement.
Abstract: Introduction: Adult-onset Still's disease is a rare systemic inflammatory disease in Africa. Observations have been published in Senegal. Materials and Methods: We conducted a retrospective descriptive study to establish the epidemiological profile of patients presenting with adult-onset Still's disease (AOSD) in a health center. The patients inclu...
Show More
Research Article
Therapeutic Benefit of Ursodeoxycholic Acid in Tamoxifen-Induced Hepatotoxicity in Rats
Issue:
Volume 12, Issue 6, December 2024
Pages:
110-119
Received:
27 September 2024
Accepted:
25 October 2024
Published:
18 November 2024
Abstract: The use of tamoxifen (TAM) for breast cancer treatment may cause hepatotoxicity. Ursodeoxycholic acid (UDCA) is a potential liver protective chemical compound. The protective effect of UDCA on TAM-induced hepatotoxicity in rats was analyzed in this study. Thirty five adult female Wistar rats grouped into 7 of n=5/group were used. The rats were treated for 10 days as follows: Group 1: (Placebo control) Water (10 mL/kg/day/oral), group 2: (Vehicle control) Ethanol 1% (1mL/kg/day) intraperitoneally (i.p), group 3: UDCA (40 mg/kg/day/oral) and group 4: TAM (45 mg/kg/day) i.p. Groups 5-7 were pretreated with UDCA (10, 20 and 40 mg/kg/day/oral) before treatment with TAM (45 mg/kg/day) i.p, respectively. On day 11, blood samples were collected and evaluated for biochemical markers. Liver tissues were analyzed for oxidative stress markers and histology. Results: TAM decreased body weight and increased liver weight significantly (p<0.01) when compared to the placebo control. Serum bilirubin, alkaline phosphatase, gamma-glutamyl transferase, lactate dehydrogenase, aminotransferases, high density lipoprotein cholesterol and liver malondialdehyde levels were significantly (p<0.001) elevated by TAM when compared to control. TAM significantly (p<0.001) decreased serum triglyceride, very low density lipoprotein cholesterol, total cholesterol, liver glutathione, catalase, superoxide dismutase and glutathione peroxidase levels when compared to the control. TAM caused liver steatosis and necrosis in rats. However, UDCA pretreatment significantly prevented the aforementioned changes caused by TAM in a dose-related fashion. UDCA may be a therapeutic option for TAM associated hepatotoxicity.
Abstract: The use of tamoxifen (TAM) for breast cancer treatment may cause hepatotoxicity. Ursodeoxycholic acid (UDCA) is a potential liver protective chemical compound. The protective effect of UDCA on TAM-induced hepatotoxicity in rats was analyzed in this study. Thirty five adult female Wistar rats grouped into 7 of n=5/group were used. The rats were trea...
Show More
